Loading...
•
Sep 30, 2022
AcelRx Q3 2022 Earnings Report
Net loss reported at $6.9 million, with DSUVIA sales increasing by 217% compared to the previous year.
Key Takeaways
AcelRx Pharmaceuticals reported a net loss of $6.9 million for Q3 2022. DSUVIA sales saw a significant increase of 217% compared to the same quarter in the previous year, reaching $0.5 million. The company is progressing with the development of Niyad™ and expects to submit an NDA for ephedrine pre-filled syringe by the end of the year.
DSUVIA sales increased by 217% year-over-year, reaching $0.5 million in Q3 2022.
Net loss attributable to common shareholders was $6.9 million, or $0.94 per basic and diluted share.
Cash, cash equivalents, and short-term investments totaled $20.9 million as of September 30, 2022.
The company is preparing for a potential Emergency Use Authorization submission for Niyad™ in the first half of 2023.
AcelRx
AcelRx
Forward Guidance
AcelRx expects to finalize an agreement for DSUVIA with a strategic partner by the end of the year and submit their ephedrine pre-filled syringe NDA by the end of this year. The second pre-filled syringe product submission is planned for the first half of next year to ensure multiple potential commercial products are available by the end of 2023.
Positive Outlook
- Potential Emergency Use Authorization for Niyad™ in the first half of 2023.
- Submission of ephedrine pre-filled syringe NDA expected by the end of this year.
- Second pre-filled syringe product submission planned for the first half of next year.
- Potential agreement for DSUVIA with a strategic partner by the end of the year.
- DZUVEO launched in Europe by partner Aguettant.